REMOVAB®

(Catumaxomab)

Documentation

Patented
Approved 2009_EMA
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: TDCC ADCC
Target: EpCAM CD3
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA